StockData
Tango Therapeutics, Inc. logo

Tango Therapeutics, Inc. (TNGX) stock

TNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/30128% above fair value
$22.11−2.06 (-8.52%)

Close on Nov 17, 2026Market cap $3.73BP/E –Yield –

Tango Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Tango Therapeutics's enterprise value was $3.33B on Nov 11, 2026, against $1.06B a year earlier. Over the last 5 years it ranged from -$110.31M to $4.13B, with a median of $414.16M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$3.33B+298.8%
2025Dec 31, 2025$835.68M+2063.1%
2024Dec 31, 2024$38.63M-94.0%
2023Dec 29, 2023$648.41M+164.4%
2022Dec 30, 2022$245.19M-46.0%
2021Dec 31, 2021$453.93M+184.4%
2020Dec 31, 2020$159.58M–

More Tango Therapeutics figures

See a number that looks wrong?